drugset
Drugs / [177Lu]Lu-AKIR001
last change Feb 2026 re-read 3 minutes ago

[177Lu]Lu-AKIR001

also known as AKIR001

targets CD44

Developed for
cervical carcinoma · head and neck cancer · non-small cell lung carcinoma · poorly differentiated thyroid gland carcinoma · thyroid gland undifferentiated (anaplastic) carcinoma · vulvar carcinoma
Investigated by
Karolinska Institutet · Karolinska University Hospital · Uppsala University

Trials 1

today NCT06639191 · Ph 0
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT06639191 Jan 2026 → Nov 2027 expected cervical carcinoma, head and neck cancer, non-small cell lung carcinoma, poorly differentiated thyroid gland carcinoma +2 Karolinska University Hospital Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as [177Lu]Lu-AKIR001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06639191 ↗
Known as AKIR001 “AKIR001, an antibody targeting CD44v6 labeled with 177Lu.” PMID 41198237 ↗ Feb 2026
Target CD44 “AKIR001, an antibody targeting CD44v6 labeled with 177Lu.” PMID 41198237 ↗ Feb 2026